EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Multifunctional ACE2-nanobody fusion design for pan-specific neutralization and cardiovascular protection in SARS coronavirus infection

Traian Sulea iD, Matthew Stuible, Maria Moreno, Alex Pelletier, Martin A Rossotti, Yuneivy Cepero-Donates, Jacqueline Slinn, Patrick Salois, Anh Tran, Melissa Hewitt, Alvaro Yogi, Nazanin Rohani und 8 weitere

Antimicrobial Agents and Chemotherapy · 06.05.2026 · 70 (5)

DOI: 10.1128/aac.00024-26 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Antimicrobial Agents and Chemotherapy, erschienen am 06.05.2026. Verfasst von Traian Sulea und 19 weiteren Autor:innen. Beteiligte Einrichtung: Human Health Therapeutics Research Centre, National Research Council Canada, Montreal, Quebec, Canada. Hauptthemen laut MEDLINE: Angiotensin-Converting Enzyme 2, Antibodies, Neutralizing, COVID-19, COVID-19 Drug Treatment. Die Arbeit nennt 58 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Severe acute respiratory syndrome coronaviruses use the ACE2 receptor for viral entry while downregulating its activity, potentially leading to hypertension and major organ injuries. Dual-action technologies based on soluble ACE2 aimed to neutralize the virus while restoring ACE2’s normal enzymatic activity. Here, we describe a novel general molecular design, VHH Spike -ACE2 ECD -VHH Albumin , in the toolbox of ACE2-centric therapeutic modalities. The optimized nanobody module VHH Spike afforded strong pan-specific binding against the entire sarbecoviral clade. This correlated with potent in vitro neutralization of pseudotyped virus variants of concern, with IC 50 values in the picomolar range. Exogenous enzymatic activity was provided by the ACE2 ECD module, which also contributed binding avidity via intrinsic homodimerization. Persistence of enzymatic activity in circulation was increased in vivo via the nanobody module VHH Albumin optimized for serum albumin binding. Single-dose therapeutic administration of lead compound 72opt-ACE2-R28 demonstrated virus neutralization in lungs of hamsters at day 5 post-infection with SARS-CoV-2. In hypertensive mice maintained under continuous injection of angiotensin II, a single dose of 72opt-ACE2-R28 normalized systolic blood pressure, maintaining a 30 mmHg reduction after 24 h. Overall, encouraging coronavirus neutralization and hypertension reduction showed magnitudes and timeframes appropriate for treatment of typical acute infections. We discuss molecular bases of interactions with coronavirus spike protein molecules and future scale-up manufacturability toward clinical development of this modular design scaffold with high potential against emerging SARS-CoV-2 variants.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Angiotensin-Converting Enzyme 2Antibodies, NeutralizingCOVID-19COVID-19 Drug TreatmentHypertensionSARS-CoV-2Single-Domain AntibodiesSpike Glycoprotein, CoronavirusAntihypertensive AgentsAnimalsMiceRatsBlood PressureMesocricetusNeutralization TestsProtein MultimerizationRats, WistarMaleRecombinant Fusion Proteins

Stichwörter der Autor:innen

ACE2 enzyme activityCOVID-19albumin bindingblood pressure reductionsingle-domain antibodyspike proteinvirus neutralization

Substanzen

Angiotensin-Converting Enzyme 2Antibodies, NeutralizingSingle-Domain AntibodiesSpike Glycoprotein, Coronavirusspike protein, SARS-CoV-2Recombinant Fusion ProteinsAntihypertensive Agents

Autor:innen und Institutionen

  • Human Health Therapeutics Research Centre, National Research Council Canada, Montreal, Quebec, Canada.
  • Institute of Parasitology, McGill University, Sainte-Anne-de-Bellevue, Quebec, Canada.
  • Human Health Therapeutics Research Centre, National Research Council Canada, Ottawa, Ontario, Canada.
  • Department of Biochemistry, Microbiology and Immunology, University of Ottawa, Ottawa, Ontario, Canada.
  • Center for Infection, Immunity and Inflammation, University of Ottawa, Ottawa, Ontario, Canada.

ORCID-Profile: Traian Sulea

Zitieren

APA

Sulea, T., Stuible, M., Moreno, M., Pelletier, A., Rossotti, M. A., Cepero-Donates, Y., Slinn, J., Salois, P., Tran, A., Hewitt, M., Yogi, A., Rohani, N., Cass, B., Lenferink, A. E. G., Tanha, J., Ling, B., Lessard, E., Delafosse, L., Sandhu, J. K., & Stanimirovic, D. (2026). Multifunctional ACE2-nanobody fusion design for pan-specific neutralization and cardiovascular protection in SARS coronavirus infection. Antimicrobial Agents and Chemotherapy, 70(5). https://doi.org/10.1128/aac.00024-26

Vancouver

Sulea T, Stuible M, Moreno M, Pelletier A, Rossotti MA, Cepero-Donates Y, et al. Multifunctional ACE2-nanobody fusion design for pan-specific neutralization and cardiovascular protection in SARS coronavirus infection. Antimicrobial Agents and Chemotherapy. 2026;70(5). doi:10.1128/aac.00024-26

BibTeX
@article{Sulea2026,
  author = {Sulea, Traian and Stuible, Matthew and Moreno, Maria and Pelletier, Alex and Rossotti, Martin A and Cepero-Donates, Yuneivy and Slinn, Jacqueline and Salois, Patrick and Tran, Anh and Hewitt, Melissa and Yogi, Alvaro and Rohani, Nazanin and Cass, Brian and Lenferink, Anne E G and Tanha, Jamshid and Ling, Binbing and Lessard, Etienne and Delafosse, Laurence and Sandhu, Jagdeep K and Stanimirovic, Danica},
  title = {Multifunctional ACE2-nanobody fusion design for pan-specific neutralization and cardiovascular protection in SARS coronavirus infection},
  journal = {Antimicrobial Agents and Chemotherapy},
  year = {2026},
  volume = {70},
  number = {5},
  doi = {10.1128/aac.00024-26}
}
Kostenlos starten →